EGFR and non-small cell lung carcinoma: Zheng et al. explored the clinical significance of paired CSF and plasma genotyping in NSCLC patients with LM for the first time, and the results showed that the identification of EGFR ex19del and T790M in CSF indicated better osimertinib efficacy (the median intracranial PFS and overall PFS were significantly longer in CSF T790M-positive patients than those in T790M-negative patients, while plasma T790M status was not associated with osimertinib efficacy).